[Disclosure of "Brugada's syndrome" with intravenous propafenone].
We present the case of a woman with familial antecedents of a brother who died suddenly at the age of 39 years, and an other with Brugada syndrome. The ECG had not shown the typical pattern of the Brugada syndrome. Based on these antecedents, we decided to perform a pharmacological test with endovenous propafenone, which revealed the electrocardiographic alterations at 10 min after the administration. This is the first case in our knowledge in which endovenous propafenone manifested a concealed Brugada syndrome.
Guevara-Valdivia
Milton E
ME
Departamento de Electrofisiología Cardiaca, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Secc XVI, 14080 México, D.F.
Iturralde Torres
Pedro
P
de Micheli
Alfredo
A
Huarte Hernández
Yaeli
Y
Galvan
Liliana
L
Lizalde
Luis Colín
LC
González-Hermosillo
Jesús A
JA
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000209:etiology; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004562:Electrocardiography; D005260:Female; D006331:Heart Diseases / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D011405:Propafenone / Q000008:administration & dosage; D013577:Syndrome
D011405:Propafenone
Desenmascaramiento del "síndrome de Brugada" con propafenona endovenosa.